You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
In Environmental Ethics and Medical Reproduction, Dr. Cristina Richie uses the term "medicalized reproduction" (MR) to describe the impact of technology on human reproduction, including from pre-conception gamete retrieval, in-vitro fertilization (IVF), and birthing suites. Unlike other areas of high-carbon health care, such as organ transplantation or chemotherapy, medicalized reproduction does not treat, cure, or prevent disease. It is supported by an economized medical industry, and as such, is open for ethical scrutiny. This book considers how technology has fundamentally changed the discussion on biomedical ethics, environmental ethics, and reproductive ethics.
Treatment strategies for breast cancer are wide-ranging and often based on a multi-modality approach, depending on the stage and biology of the tumour and the acceptance and tolerance of the patient. They may include surgery, radiotherapy, and systemic therapy (endocrine therapy, chemotherapy, and targeted therapy). Advances in technologies such as oncoplastic surgery, radiation planning and delivery, and genomics, and the development of novel systemic therapy agents alongside their evaluation in ongoing clinical trials continue to strive for improvements in outcomes. In this Special Issue, we publish a collection of studies looking at all forms of therapeutic strategies for early and advanced breast cancer, focusing on their outcomes, notably survival.
Dieses Buch vermittelt den behandelnden Gynäkologen, Gynäko-Onkologen und Reproduktionsmedizinern praxisorientiert und gegliedert nach verschiedenen gynäkologischen Tumorentitäten wissenschaftliche Evidenz als Beratungsgrundlage und praktische Empfehlungen zum Thema Fertilitätserhalt.
This book is a comprehensive guide to the techniques, clinical applications, and benefits of the different forms of liquid biopsy employed in patients with a variety of tumor types, including lung, breast and colorectal cancer. Offering detailed explanations, it discusses the how changes in tumors can be tracked using these cutting-edge technologies, which enable the detection and analysis of diverse circulating biomarkers: tumor cells, tumor DNA, tumor RNA (free or in exosomes), and fluid biomarkers identifiable by means of targeted proteomics. The use of such advanced technologies is enabling us to tackle questions and problems in a way that was not possible just a few years ago. We now have at our disposal an effective means of overcoming the problem of intratumor heterogeneity, which has limited the value of conventional biopsy approaches. As a consequence, oncology practice is about to change radically, toward truly personalized precision medicine. This book provides both clinicians and researchers with a thorough and up-to-date overview of progress in the field.
Das Manual ist als klinischer Leitfaden für alle Berufsgruppen gedacht, die an der Versorgung von Patientinnen mit Ovarialkarzinom beteiligt sind. Die einzelnen Kapitel wurden auf der Basis neuer Daten interdisziplinär aktualisiert. Sowohl für die Diagnostik als auch für die Therapie und Nachsorge werden klare, objektive und praxisnahe Empfehlungen ausgesprochen. Soweit vorhanden, wurden diese mit evidenzbasierten Daten unterlegt. Auch aktuelle Daten zu neuen Genmutationen bei den hereditären Ovarialkarzinomen finden sich in dem Manual, ebenso wie neue molekularbiologische Therapieansätze, die derzeit in klinischen Studien untersucht werden.
Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today's available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists. - Covers the diagnosis, treatments and targeted therapies, and management of breast cancers that are HER2-positive. - Contains sections on background and testing, advanced disease, therapeutics, and toxicity considerations. - Includes a timely section on innovative future therapies.
Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers.
The book 'Breast Cancer and Surgery' summarizes the treatment options from the onset of breast carcinogenesis to early-local advanced and metastatic breast cancer. Chemotherapy alternatives, drug resistance and local and surgical treatment preferences are extensively discussed and this information is especially directed at clinicians, researchers, and students. This book includes a comparison between different chemotherapy agents and targeted therapies with published phase II-III studies. The importance of palliative care and dietary supplements administered during the treatment course in reducing the comorbidity of patients is emphasized. Photodynamic treatments have been included in this book. A comprehensive and up-to-date information exchange that can be accessed through a single source is provided to all researchers interested in breast cancer.